Praveen Tyle

Praveen has served as a director since June 2008. He is currently President & CEO of Invectys, Inc, a immuno-oncology company spun out of the world renown Pasteur Institute, Paris. Previously, he was Executive Vice President of Research & Development at Lexicon Pharmaceuticals, The Woodlands, Texas. Dr. Tyle until February 2016 was President, Chief Executive Officer and Member of the Board of Directors of Osmotica Pharmaceutical Corp. He led and closed the merger of Osmotica with two other companies which closed in February 2016. He previously served as global Executive Vice President, Chief Scientific Officer and Managing Director of Osmotica Pharmaceutical Corp.’s Marietta, Georgia site. Prior to joining Osmotica, Dr. Tyle served as Executive Vice President and Chief Science Officer for the United States Pharmacopeia (“USP”). Prior to joining USP, Dr. Tyle served as Senior Vice President and Global Head of Business Development and Licensing at Novartis OTC, as well as Senior Vice President & Global Head of Research and Development. Dr. Tyle has over 30 years of experience in the pharmaceutical industry with the majority of his tenure in senior executive leadership positions in areas of research and development, manufacturing, quality, business development and operations. He also is a independent member of the board of Orient EuroPharma Co., Ltd. of Taiwan and member of the advisory board of Pharmascience, Montreal, Canada. Dr. Tyle holds a doctorate in pharmaceutics and pharmaceutical chemistry from the Ohio State University and a Bachelor in Pharmacy (honors) from the Indian Institute of Technology, Banaras Hindu University in India.